Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size.
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met.
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.